Earnings Call

As VerticalScope preps its 2025 results, investors watch if its pivot to AI and e-commerce can overcome ad market and search engine challenges.

Compass Diversified sets its earnings date, putting its post-Lugano strategy and portfolio health under intense scrutiny from investors.

With COVID revenue fading, QuidelOrtho will use a key conference to prove its diversified diagnostics model can deliver on growth, margins, and cash flow.

As BJ’s prepares to report Q4 results, investors are watching if a pizza relaunch and new efficiencies can overcome industry-wide cost pressures.

The defense contractor signals a strategic shift after lost contracts and procurement delays slash its 2027 revenue outlook, even as profits beat expectations.

As OneSpaWorld prepares its Q4 results, all eyes are on the wellness giant as a barometer for luxury travel spending and its tech-driven future.

As Omada Health preps its 2025 results, all eyes are on whether its blend of tech, human coaching, and GLP-1 support can deliver sustainable profits.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

With its AI strategy in the spotlight and competitors gaining ground, all eyes are on Cisco's Feb 11 earnings call for signs of growth and future direction.

With its stock under pressure, Insperity's upcoming Q4 earnings and 2026 outlook will be a critical test of its strategy to combat rising healthcare costs.

As SmartStop sets its Q4 earnings date, investors watch to see if its aggressive expansion and acquisition spree can translate into sustained profitability.

Kodiak Gas Services raises its dividend, but with earnings on the horizon, can the energy infrastructure giant sustain its generous shareholder returns?

Generac's upcoming earnings report will reveal its navigation of a weak outage year while chasing a data center boom. What does it mean for investors?

As Mirion prepares to release its 2025 results, investors are eyeing strong nuclear orders and medical segment growth. What will the numbers reveal?

Medical device firm CVRx is under investigation after its stock nosedived. Did management mislead investors about its salesforce stability?

Progyny signals better-than-expected 2025 results on robust member engagement, sparking analyst upgrades and sending its stock soaring ahead of a key conference.

Amid market headwinds, JD.com cancels $3B in shares to boost value, signaling deep confidence while juggling costly strategic growth initiatives.

The semiconductor equipment firm will release crucial 2025 and 2026 financial guidance in January, offering a key early test of the industry's momentum.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

A major acquisition turned sour, a 25% stock crash, and now a class action lawsuit. Inside Perrigo's costly infant formula venture and what it means.